Ray Jordan Joins Moderna as Chief Corporate Affairs Officer
June 15 2020 - 8:00AM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced that Ray Jordan has joined Moderna as
Chief Corporate Affairs Officer, effective Monday, June 15, 2020.
He will serve on Moderna’s Executive Committee and report to Chief
Executive Officer Stéphane Bancel.
“It has been a pleasure working with Ray on a consulting basis
over the last four months and I am thrilled to welcome him as our
Chief Corporate Affairs Officer and to the Executive Committee,”
said Stéphane Bancel, Chief Executive Officer of Moderna. “Ray has
an impressive track record operating across geographies and at
scale at Amgen, J&J and Pfizer. His strategic communications
and management experience at global commercial biopharmaceutical
companies will be a tremendous asset as we continue into late-stage
commercial development of our COVID-19 vaccine and our CMV
vaccine.”
Mr. Jordan served as Senior Vice President, Corporate Affairs at
Amgen (Nasdaq: AMGN) from 2012 through 2019. At Amgen, he was
responsible for all internal and external communications, issues
management and philanthropy. During his seven-year tenure, he led
strategic communications for an unprecedented six product launches.
Prior to Amgen, Mr. Jordan spent nine years at Johnson &
Johnson (NYSE: JNJ), where he led corporate communications and
public affairs for more than 250 operating companies in 60
countries. Previously, Mr. Jordan held a range of positions over
the course of 17 years at Pfizer (NYSE: PFE), most recently as Vice
President, Communications and Information. He has also served as
chair of PhRMA's public affairs section and of the National
Pharmaceutical Council's User Group.
“I’ve been keenly interested in Moderna’s mRNA platform and its
potential to build a new class of medicine for years. I’ve had the
privilege of getting to know the executive committee on a
consulting basis over the last four months and I am incredibly
impressed with the Moderna team and culture. I look forward to
building the corporate affairs team and supporting Moderna’s
mission to bring mRNA medicines and vaccines to patients and
populations during this exciting time of growth for the
company.”
Mr. Jordan received his Master of Business Administration in
marketing and finance from Columbia University and his Bachelor of
Arts with concentration in psychology and mathematics from Yale
University.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a
new class of transformative medicines for patients. mRNA medicines
are designed to direct the body’s cells to produce intracellular,
membrane or secreted proteins that can have a therapeutic or
preventive benefit and have the potential to address a broad
spectrum of diseases. The company’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing Moderna the capability to pursue in
parallel a robust pipeline of new development candidates. Moderna
is developing therapeutics and vaccines for infectious diseases,
immuno-oncology, rare diseases, cardiovascular diseases, and
autoimmune and inflammatory diseases, independently and with
strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca PLC
and Merck & Co., Inc., as well as the Defense Advanced Research
Projects Agency (DARPA), an agency of the U.S. Department of
Defense, and the Biomedical Advanced Research and Development
Authority (BARDA), a division of the Office of the
Assistant Secretary for Preparedness and Response (ASPR) within
the U.S. Department of Health and Human Services (HHS). Moderna
has been named a top biopharmaceutical employer by Science for the
past five years. To learn more, visit www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200615005184/en/
Moderna Contacts Media: Colleen Hussey Senior Manager,
Corporate Communications 203-470-5620
Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Head of Investor Relations
617-209-5834 Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024